KindlyMD(TM) Announces $500,000 Share Repurchase Program
KindlyMD (NASDAQ:KDLY), a patient-first healthcare and healthcare data company, has announced a $500,000 share repurchase program. The program, authorized by the Board of Directors, allows the company to repurchase its common shares from time to time, based on market conditions. CEO Tim Pickett stated that this move demonstrates confidence in KindlyMD's current valuation and future growth opportunity, as well as a commitment to enhancing shareholder value.
The repurchases may be made in the open market, through private negotiations, or other means in compliance with securities laws. The program has no time limit and does not obligate the company to repurchase any specific amount of shares. The timing and amount of repurchases will be determined by management based on various factors, including market conditions and regulatory requirements.
KindlyMD (NASDAQ:KDLY), un'azienda sanitaria e di dati sanitari orientata al paziente, ha annunciato un programma di riacquisto di azioni da 500.000 dollari. Il programma, autorizzato dal Consiglio di Amministrazione, consente all'azienda di riacquistare le proprie azioni ordinarie di volta in volta, in base alle condizioni di mercato. Il CEO Tim Pickett ha dichiarato che questa mossa dimostra fiducia nella valutazione attuale di KindlyMD e nelle opportunità di crescita future, oltre a un impegno per migliorare il valore per gli azionisti.
I riacquisti possono essere effettuati sul mercato aperto, attraverso negoziazioni private o altri mezzi nel rispetto delle leggi sui titoli. Il programma non ha una scadenza e non obbliga l'azienda a riacquistare un numero specifico di azioni. Il timing e l'importo dei riacquisti saranno determinati dalla direzione in base a vari fattori, comprese le condizioni di mercato e i requisiti normativi.
KindlyMD (NASDAQ:KDLY), una empresa de atención médica y datos de atención médica centrada en el paciente, ha anunciado un programa de recompra de acciones de 500,000 dólares. El programa, autorizado por la Junta Directiva, permite a la empresa recomprar sus acciones comunes de vez en cuando, según las condiciones del mercado. El CEO Tim Pickett declaró que este movimiento demuestra confianza en la valoración actual de KindlyMD y en las oportunidades de crecimiento futuro, así como un compromiso por mejorar el valor para los accionistas.
Las recompras pueden realizarse en el mercado abierto, a través de negociaciones privadas u otros medios de conformidad con las leyes de valores. El programa no tiene límite de tiempo y no obliga a la empresa a recomprar una cantidad específica de acciones. El momento y la cantidad de las recompras serán determinados por la dirección en función de varios factores, incluidas las condiciones del mercado y los requisitos regulatorios.
KindlyMD (NASDAQ:KDLY), 환자 우선의 헬스케어 및 헬스케어 데이터 기업,가 50만 달러 규모의 자사주 매입 프로그램을 발표했습니다. 이 프로그램은 이사회에 의해 승인되었으며, 회사는 시장 상황에 따라 자사 보통주를 수시로 매입할 수 있습니다. CEO Tim Pickett는 이 조치가 KindlyMD의 현재 가치와 향후 성장 가능성에 대한 신뢰를 나타내며, 주주 가치를 높이겠다는 의지를 보여준다고 말했습니다.
매입은 공개 시장에서, 사적 협상 또는 기타 수단을 통해 증권 법규를 준수하여 이루어질 수 있습니다. 이 프로그램은 시간 제한이 없으며 회사가 특정 수량의 주식을 매입해야 할 의무가 없습니다. 매입의 시기와 금액은 시장 상황 및 규제 요구 사항을 포함한 여러 요인에 따라 경영진에 의해 결정됩니다.
KindlyMD (NASDAQ:KDLY), une entreprise de soins de santé et de données de santé axée sur le patient, a annoncé un programme de rachat d'actions de 500 000 dollars. Le programme, autorisé par le Conseil d'administration, permet à l'entreprise de racheter ses actions ordinaires de temps en temps, en fonction des conditions du marché. Le PDG Tim Pickett a déclaré que cette démarche démontre la confiance dans l'évaluation actuelle de KindlyMD et les opportunités de croissance future, ainsi qu'un engagement à renforcer la valeur pour les actionnaires.
Les rachats peuvent être effectués sur le marché libre, par le biais de négociations privées ou d'autres moyens en conformité avec les lois sur les valeurs mobilières. Le programme n'a pas de limite de temps et n'oblige pas l'entreprise à racheter une quantité spécifique d'actions. Le moment et le montant des rachats seront déterminés par la direction en fonction de divers facteurs, y compris les conditions du marché et les exigences réglementaires.
KindlyMD (NASDAQ:KDLY), ein patientenorientiertes Gesundheits- und Gesundheitsdatunternehmen, hat ein Aktienrückkaufprogramm über 500.000 Dollar bekannt gegeben. Das Programm, das vom Vorstand genehmigt wurde, ermöglicht es dem Unternehmen, von Zeit zu Zeit, je nach Marktbedingungen, seine Stammaktien zurückzukaufen. CEO Tim Pickett erklärte, dass dieser Schritt Vertrauen in die aktuelle Bewertung von KindlyMD und die zukünftigen Wachstumschancen zeigt, sowie ein Engagement zur Verbesserung des Shareholder-Value.
Die Rückkäufe können auf dem offenen Markt, durch private Verhandlungen oder andere Mittel unter Einhaltung der Wertpapiergesetze erfolgen. Das Programm hat keine zeitliche Begrenzung und verpflichtet das Unternehmen nicht, eine bestimmte Anzahl von Aktien zurückzukaufen. Der Zeitpunkt und die Menge der Rückkäufe wird von der Unternehmensleitung basierend auf verschiedenen Faktoren, einschließlich der Marktbedingungen und regulatorischen Anforderungen, festgelegt.
- Authorization of a $500,000 share repurchase program
- Demonstrates management's confidence in the company's valuation and growth prospects
- Potential to enhance shareholder value through stock buybacks
- Flexibility in timing and execution of repurchases
- None.
Insights
The announcement of a
Share buybacks can be seen as a positive signal, indicating management's belief that the stock is undervalued. It can potentially boost earnings per share and stock price by reducing the number of outstanding shares. However, for a smaller company like KindlyMD, investors should consider whether this capital could be better utilized for growth initiatives or operational improvements.
The open-ended nature of the program, without a specified time limit, provides flexibility but also uncertainty about the actual execution. Investors should monitor the company's cash position and future financial reports to assess the impact of this program on KindlyMD's liquidity and growth prospects.
KindlyMD's decision to implement a share repurchase program could be interpreted as a strategic move to support its stock price and signal confidence to the market. For a small-cap company in the healthcare sector, this action might be aimed at attracting investor attention and potentially increasing trading volume.
However, it's important to consider the broader context. The healthcare industry, particularly companies integrating traditional and alternative therapies, faces regulatory challenges and market skepticism. Investors should evaluate whether this buyback aligns with KindlyMD's long-term growth strategy and if it's the most effective use of capital for a company of this size.
The impact on stock liquidity could be significant, given the company's relatively small market cap. While the buyback might provide short-term price support, its long-term effectiveness will depend on KindlyMD's fundamental performance and ability to execute its business model successfully.
SALT LAKE CITY, UT / ACCESSWIRE / October 15, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to
Tim Pickett, Chief Executive Officer, "Our stock buyback program demonstrates our confidence in KindlyMD's current valuation, future growth opportunity and commitment to enhancing shareholder value."
The Company's proposed repurchases may be made in the open market, in privately negotiated transactions, or otherwise in accordance with applicable securities laws and other requirements. The amount and timing of any repurchases will be determined at management's discretion and depend on a variety of factors, including business, economic and market conditions, regulatory requirements, prevailing stock prices and other considerations. The share repurchase program has no time limit, does not obligate the Company to repurchase any dollar amount or number of shares of common stock, and may be amended, suspended or discontinued at any time.
About KindlyMD
KindlyMD™️ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including, but not limited to, the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
KindlyMD@KCSA.com
SOURCE: KindlyMD, Inc
View the original press release on accesswire.com
FAQ
What is the value of KindlyMD's (KDLY) newly announced share repurchase program?
When does KindlyMD's (KDLY) share repurchase program expire?
How will KindlyMD (KDLY) execute its share repurchase program?
What factors will determine KindlyMD's (KDLY) share repurchases under the new program?
